Baijin Life Science Holdings Ltd.: management transactions · Hong Kong · HKEX HKEX:baijin-life-science-holdings-ltd HK HK · HKEX Mcap 461M€ Consumer Cyclical
Browse the full directors' dealings record of Baijin Life Science Holdings Ltd., a listed equity based in Hong Kong. Shares are quoted on HK HK, under the supervision of HKEX. Operating in the Consumer Cyclical sector, Baijin Life Science Holdings Ltd. has logged 9 insider filings. Market capitalisation: €461.5m. The latest transaction was reported on 29 April 2026 — Purchase. Among the most active insiders: CHENG Chi Kin. All data is free.
Financial data FY ended March 2025 · cache
Income statement
Revenue 135.6 M€
Gross profit 42.0 M€ 31% margin
Net income −316 k€ 6.7% margin
Valuation
PER (trailing) 49.5x
P/Book 2.7x
Beta -0.25
Balance sheet & cash
Market cap 461.5 M€
Total debt 99.9 M€
Free Cash Flow −33.0 M€
Debt / Equity 54%
Profitability & ownership
ROE 3.3%
ROA 1.2%
% insiders 32.7%
% institutions 0.0%
Last declaration on 29 April 2026
Declarations 9 total
Executives ● Purchase3 HKEX
1,000,000 shares
HKEX:DA20260428E00528 · 24 Apr 2026
Ideal exit: 19 Jan 2027 (T+270) Executives ● Purchase3 HKEX
932,000 shares
HKEX:DA20260428E00519 · 24 Apr 2026
Ideal exit: 19 Jan 2027 (T+270) Executives ● Purchase3 HKEX
2,933,765 shares
HKEX:DA20260428E00413 · 24 Apr 2026
Ideal exit: 19 Jan 2027 (T+270) Executives ● Purchase3 HKEX
2,000,000 shares
HKEX:DA20260428E00340 · 24 Apr 2026
Ideal exit: 19 Jan 2027 (T+270) Executives ● Purchase3 HKEX
2,933,765 shares
HKEX:DA20260429E00164 · 24 Apr 2026
Ideal exit: 19 Jan 2027 (T+270) Executives ● Purchase3 HKEX
2,933,765 shares
HKEX:DA20260429E00060 · 24 Apr 2026
Ideal exit: 19 Jan 2027 (T+270) Executives ● Purchase3 HKEX
932,000 shares
HKEX:DA20260428E00535 · 24 Apr 2026
Ideal exit: 19 Jan 2027 (T+270) Executives ● Purchase3 HKEX
9,322,540 shares
HKEX:DA20260428E00086 · 24 Apr 2026
Ideal exit: 19 Jan 2027 (T+270) Executives ● Purchase3 HKEX
932,000 shares
HKEX:DA20260428E00295 · 24 Apr 2026
Ideal exit: 19 Jan 2027 (T+270)